양성 및 악성 갑상샘 병변에서의 galectin-3, skp2, p27, cyclin D1 발현의 연관성
Correlation of Expression of galectin-3, skp2, p27 and cyclin D1 in Benign and Malignant Thyroid Lesions
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Background : The overexpression of cyclin D1 and galectin-3 and the loss of p27 in thyroid cancers have recently been reported by many studies. The S-phase kinase associated protein 2 (skp2) plays an important role in the degradation of p27. We compared the correlation of the expressions of galectin-3, p27, cyclin D1 and skp2 in thyroid lesions. Methods : Sixty five cases were included in this study and immunohistochemical staining for galectin-3, skp2, p27 and cyclin D1 was performed. Results : The expression of galectin-3 increased in the order of nodular hyperplasia, follicular adenoma, follicular carcinoma and papillary carcinoma (p<0.01). The expression rate of skp2 was 0% for nodular hyperplasia, 16.7% for follicular adenoma, 33.3% for follicular carcinoma and 16.7% for papillary carcinoma. The loss of the expression of p27 was more frequently detected in papillary carcinoma ascompared with nodular hyperplasia (p<0.01). The increased expression of cyclin D1 was noted in follicular adenoma and carcinoma as compared with nodular hyperplasia (p=0.043). The expression of galectin-3 was related with the loss of a p27 expression (p<0.01), and the expression of skp2 was related with the expression of the cyclin D1 (p=0.022). Conclusions : Galectin-3 appears to be the most useful marker for making the diagnosis of thyroid lesions. The loss of a p27 expression can help differentiate nodular hyperplasia and papillary carcinoma, and the determining the expression of cyclin D1 may be helpful for the differential diagnosis of nodular hyperplasia and follicular neoplasm.
참고문헌 (30)
- Haugen BR, "Initial treatment of differentiated thyroid carcinoma", Rev Endocr Metab Disord, 1, pp.139~145 (2000)
- Mazzaferri EL, "NCCN Thyroid carcinoma practice guidelines", NCCN Proceedings, pp.391~442 (2000)
- Sherman SI, "Prospective multi center study of thyroid carcinoma treatment- initial analysis of staging and outcome", Cancer, 83, pp.1012~1021 (1998)
- Baloch Z, "Encapsulated follicular variant of papillary thyroid carcinoma", Am J Clin Pathol, 118, pp.603~605 (2002)
- Baloch ZW, "Diagnosis of ‘‘follicular neoplasm’’: a gray zone in thyroid fine needle aspiration cytology", Diagn Cytopathol, 26, pp.41~44 (2002)
- Kini SR, "Cytopathology of follicular lesions of thyroid gland", Diagn Cytopathol, 1, pp.123~132 (1985)
- Orlandi F, "Galectin-3 is a presurgical marker of human thyroid carcinoma", Cancer Res, 58, pp.3015~3020 (1998)
- Bartolazzi A, "Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions", Lancet, 357, pp.1644~1650 (2001)
- Papotti M, "Role of galectin-3 immunodetectionin the cytological diagnosis of thyroid cystic papillary carcinoma", Eur J Endocrinol, 147, pp.515~521 (2002)
- Savin SB, "Expression of galectin-1 and galectin-3 in human fetal thyroid gland", J Histochem Cytochem, 51, pp.479~483 (2003)
- Volante M, "Diagnostic role of galectin-3 in follicular thyroid tumors", Virchow Arch, 444, pp.309~312 (2004)
- Kim KR, "Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells", Cancer Res, 59, pp.4148~4154 (1999)
- Hall M, "Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer", Adv Cancer Res, 68, pp.67~108 (1996)
- Hunter T, "Cyclins and cancer II: cyclin D and CDK inhibitors come of age", Cell, 79, pp.573~582 (1994)
- Lazzereschi D, "Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas", Int J Cancer, 76, pp.806~811 (1998)
- Sherr CJ, "Inhibitors of mammalian G1 cyclin-dependent kinases", Genes Dev, 9, pp.1149~1163 (1995)
- Reed SI, "G1 control in mammalian cells", J Cell Sci, 18, pp.69~73 (1994)
- Carr K, "Immunohistochemical analysis of thyroid carcinomas utilizing antibodies to p53 and Ki-67", Appl Immunohistochem, 1, pp.201~207 (1993)
- Catzavelos C, "Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer", Nat Med, 3, pp.227~230 (1997)
- Porter P, "Expression of cell-cycle regulator p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients", Nat Med, 3, pp.222~224 (1996)
- Loda M, "Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas", Nat Med, 3, pp.231~234 (1997)
- Masuda TA, "Clinical and biological significance of S-phase kinase associated protein 2 (skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by skp2 overexpression, possibly via p27 proteolysis", Cancer Res, 62, pp.3819~3825 (2002)
- Slingerland J, "Regulation of the cdk inhibitor p27 and its deregulation in cancer", J Cell Physiol, 183, pp.10~17 (2000)
- Nakayama K, "Targeted disruption of skp2 results in accumulation of cyclin E and p27kip1. polyploidy and centrosome overduplication", EMBO J, 19, pp.2069~2081 (2000)
- Gstaiger M, "Skp2 is oncogenic and overexpressed in human cancers", Proct Natl Acad Sci USA, 98, pp.5043~5048 (2001)
- Trocone G, "P27kip1 protein expression in Hashimoto`s thyroiditis", J Clin Pathol, 56, pp.587~591 (2003)
- Erikson LA, "Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors", Mod Pathol, 11, pp.169~174 (1998)
- LaBaer J, "New funtional activities for the p21 family of CDK inhibitors", Genes Dev, 11, pp.847~862 (1997)
- Motti ML, "Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K", AKT pathway. Regulation of p27kip1 expression and localization, 2005, pp.166, 737~749
- Paron I, "Nuclear localization of galectin-3 in transformed thyroid cells: a role in transcriptional regulation", Biochem Biophys Res Commun, 302, pp.545~553 (2003)